Business
Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
PONTE VEDRA, Fla., August 05, 2025--Cadrenal announces clinical trial initiation plans for tecarfarin in patients with end-stage kidney disease (ESKD) who are transitioning to dialysis
About this update from Cadrenal Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2289,"height":530,"url":"https://media.zenfs.com/en/business-wire.com/27b2cd6043703d6691bd6d8c10578457"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/khwYDDuI88xw8dzor3XyQw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIyMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/27b2cd6043703d6691bd6d8c10578457","width":960,"height":222},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/s_b21OtbP6YTBAZLt6I5iw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01NTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/27b2cd6043703d6691bd6d8c10578457","width":1200,"height":278}},"lazy":false},{"type":"text","content":"Advances knowledge about the use of tecarfarin in patients with severe kidney impairment, including dialysis","length":108,"tagName":"p","attribs":{}},{"type":"text","content":"Pivotal step forward in pursuit of ESKD + Atrial Fibrillation (AFib) registration trial","length":87,"tagName":"p","attribs":{}},{"type":"text","content":"Addresses a critical current treatment gap in patients with ESKD","length":64,"tagName":"p","attribs":{}},{"type":"text","content":"PONTE VEDRA, Fla., August 05, 2025--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing transformative therapeutics that specifically address limitations of current anticoagulation therapy, today announced clinical trial initiation plans for its lead late-stage drug candidate, tecarfarin, in patients with ESKD who are transitioning to dialysis. Enrollment is planned to begin later this year and will include patients with and without atrial fibrillation (AFib).","length":523,"tagName":"p"},{"type":"text","content":"Patients with severe kidney disease are already at high risk for thrombotic cardiovascular events such as myocardial infarction and stroke, along with a much greater risk of AFib and venous thromboembolism compared to subjects with normal kidney function. When ESKD patients require dialysis, their transition period comes with even greater risk of myocardial infarction, stroke, and a substantial increase in mortality.","length":420,"tagName":"p"},{"type":"text","content":""There is a critical need for safe, effective anticoagulants for use in ESKD patients," said Quan...